Royal Victoria Regional Health Centre (RVH) in Barrie is among the nearly 40 hospitals across Canada that will participate in a clinical trial examining potential COVID-19 therapies.
The trial is part of a World Health Organization global study. The Canadian contribution to the study, dubbed CATCO, is coordinated by Sunnybrook in Toronto. Patients requiring hospitalization because of COVID-19 at RVH may be eligible to participate in the study.
The CATCO trial is expected to run for about two years and will examine leading drug candidates in the fight against COVID-19. Those drugs will not include hydroxychloroquine and lopinavir-ritonavir, recently discontinued by the WHO due to lack of effect.
“RVH’s participation in the CATCO trial offers Simcoe Muskoka residents an opportunity to access potentially helpful treatments for COVID-19,” says Christine Di Marco, RVH Clinical Trials coordinator, adding, “RVH’s recent focus on teaching and research has prepared us to respond to challenging health trends and needs by rallying together to find new solutions.”
Those RVH patients participating in the trial will receive either supportive care or the study medication plus supportive care.